# Teal Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/teal-bio

- Industry: Medical Devices & Equipment
- Headquarters: Somerville, US
- Website: www.teal-bio.com
- Total disclosed funding: $3.1M
- Latest round: Series A (Nov 9, 2021)
- Investors on record: 2

## About

Teal Bio, Inc. develops innovative respiratory protection solutions, focusing on enhancing comfort and communication for healthcare professionals through its advanced Teal Respirator.Teal Bio specializes in producing respiratory protection products, particularly the Teal Respirator, established in 2020 and headquartered in Somerville, US. The company was founded by Adam Wentworth and Giovanni Traverso. Teal Bio has completed three funding deals, with the latest being a Series A round, securing USD 1.000 mn from WHX Pension Plan Trust on December 31, 2023, which matches the total amount raised.Teal Bio specializes in the development of innovative respiratory protection solutions, with a primary focus on the Teal Respirator. This product is designed to address discomfort and communication challenges associated with traditional disposable masks. The Teal Respirator features a soft silicone seal that minimizes skin irritation, adjustable straps for a custom fit, and a transparent facepiece that enhances interpersonal communication while allowing for reuse after cleaning. The company aims to alleviate the common issues associated with conventional masks, such as heat buildup and environmental harm caused by single-use plastics. Teal Bio's products are targeted towards healthcare providers, including hospitals and clinics, primarily in North America and Europe, with plans to expand further into international markets.Teal Bio generates revenue through direct sales of its flagship product, the Teal Respirator, to healthcare institutions and professionals. The company operates on a business-to-business (B2B) model, supplying its respirators directly to hospitals and clinics, where bulk purchasing agreements may be established to facilitate ongoing supply needs. Pricing strategies include tiered pricing based on order volume, allowing institutions to benefit from cost efficiencies as they scale their purchases. Additionally, the company may engage in partnerships with distributors to enhance market reach and streamline logistics. The revenue model is designed to support sustained growth as the healthcare sector increasingly prioritizes effective respiratory solutions amidst evolving market demands.Teal Bio plans to leverage its recent Series A funding of USD 1.000 mn raised in December 2023 to develop new products and expand its market presence. The company is designing additional respiratory products aimed at providing enhanced protection and comfort, though specific release dates are not provided. Teal Bio also targets expansion into new geographical markets, particularly in Europe and Asia, to broaden its customer base and meet growing demands for advanced respiratory solutions.

## Funding rounds

- Series A, Nov 9, 2021, $2.5M — Caligan Partners, Innocreative Capital
- Seed, Dec 2, 2020, $0.6M — Innocreative Capital

## Investors

- Innocreative Capital (https://capitalatlas.ai/funds/innocreative-capital) — Seed, Series A
- Caligan Partners — Series A